BEIJING: China has added 107 drugs to its updated medical insurance drug list, including a record 51 first-in-class innovative medicines, while prioritizing treatments for cancer, rare diseases and other condi-tions with significant unmet clinical needs, the National Healthcare Security Administration said.
The updated list, released on Saturday, will take effect on Jan 1, 2027. The administration has adjusted the list annually for nine consecutive years.
With 34 drugs removed due to limited clinical value, better alterna-tives or supply constraints, the updated insurance catalog now in-cludes 3,331 drugs, comprising 1,935 Western medicines and 1,396 traditional Chinese medicine products.
Among the newly added drugs, 31 are for tumors, 18 target rare diseases and 24 address chronic conditions, while the remainder cover areas such as infectious diseases and mental health.
Huang Xinyu, head of the administration’s medical service man-agement department, said priority is given to drugs with significant clinical value that are also affordable for national medical insurance funds. The list also favors innovative, reasonably priced drugs that meet the needs of vulnerable groups.
One example is the inclusion of three non-factor therapies for he-mophilia, a rare genetic disorder that can cause spontaneous and severe bleeding.
Compared with conventional clotting factor concentrate infusions, Huang said, non-factor therapies offer effective treatment outcomes at a cost that is manageable for medical insurance funds.
The administration will continue to monitor the real-world efficacy of these therapies and their impact on fund sustainability, which will in-form future price negotiations with drug manufacturers, he added.
The list also marks the inclusion of the first CAR-T cell therapy, a novel and often expensive treatment for cancer.
Tian Feng, CEO of JW Therapeutics in Shanghai, which develops the CAR-T cell therapy for lymphoma, said more than 1,200 pa-tients have benefited from the treatment since its market approval in 2021.
“Inclusion in the basic insurance list means more patients can ben-efit, and it also opens up broader opportunities for continued inno-vation at the company,” he added.
In addition, the administration unveiled the updated commercial in-surance innovative drug list, the second iteration since its inception in 2025.
The list included 12 new drugs, bringing the total to 28. It is focused on highly innovative medicines that are too costly for basic insur-ance but are recommended for commercial health coverage.
Huang said that as of October, the first version of the commercial insurance list was estimated to have bolstered pharmaceutical sales by about 600 million yuan ($89 million), with a 70 percent in-crease in monthly sales.
Newly added treatments include frontier therapies such as cell and gene therapies, as well as more advanced therapies for rare dis-eases and cancer.
Zhang Ke, director of the administration, said a series of measures have been implemented to facilitate insurance reimbursement and the clinical application of innovative drugs.
Currently, annual drug sales driven by the medical insurance list have surpassed 170 billion yuan ($25 billion), four times higher than five years ago. –The Daily Mail-China Daily news exchange item



